{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.94","upperLimit":"5.98","value":"5.03"},{"groupId":"OG001","lowerLimit":"5.78","upperLimit":"7.52","value":"6.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"349"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"This measure looks at how long all participants in the primary study live without their cancer getting worse after being assigned to a treatment group.\n\nProgression-Free Survival (PFS) is defined as the time from when a participant is assigned to a treatment group (randomization) until their cancer is first shown to get worse (progress), based on reviews by independent experts who do not know which treatment the participant received. These experts use standard rules (called RECIST 1.1) to decide if the cancer has progressed. If a participant dies before their cancer is shown to get worse, the date of death will be used as the time their disease progressed. If a participant's cancer does not get worse and they do not die during the study, their PFS will be measured up to the date of their last tumor check.\n\nThis helps to understand whether the treatment can help participants live longer without their cancer progressing.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg every three weeks (Q3W) for up to 4 doses followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Primary Study","id":"OG000","title":"Treatment 1"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Primary Study","id":"OG001","title":"Treatment 2"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants - Primary Study","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)","title":"Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in All Randomized Participants for Primary Study","type":"SECONDARY","unitOfMeasure":"Months"}